Ordering Recommendation

Use this mass spectrometry test to measure a wide range of testosterone concentrations. Most useful when low concentrations are expected, regardless of the patient’s sex assigned at birth. Use to monitor testosterone-suppressing hormone therapies (eg, antiandrogens or estrogens). Free or bioavailable testosterone measurements may provide supportive information.

To compare this test to other testosterone tests, refer to the ARUP Testosterone Tests Comparison table.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Collect between 6-10 a.m.


Serum separator tube or green (sodium or lithium heparin).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP standard transport tube. (Min: 0.2 mL)

Storage/Transport Temperature


Unacceptable Conditions

EDTA plasma.


After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months


Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry




1-5 days

Reference Interval

Effective August 19, 2013

Premature (26-28 weeks) 5-16 ng/dL 59-125 ng/dL
Premature (31-35 weeks) 5-22 ng/dL 37-198 ng/dL
Newborn 20-64 ng/dL 75-400 ng/dL
1-5 months Less than 20 ng/dL 14-363 ng/dL
6-24 months Less than 9 ng/dL Less than 37 ng/dL
2-3 years Less than 20 ng/dL Less than 15 ng/dL
4-5 years Less than 30 ng/dL Less than 19 ng/dL
6-7 years Less than 7 ng/dL Less than 13 ng/dL
8-9 years 1-11ng/dL 2-8 ng/dL
10-11 years 3-32 ng/dL 2-165 ng/dL
12-13 years 6-50 ng/dL 3-619 ng/dL
14-15 years 6-52 ng/dL 31-733 ng/dL
16-17 years 9-58 ng/dL 158-826 ng/dL
18-39 years 9-55 ng/dL 300-1080 ng/dL
40-59 years 9-55 ng/dL 300-890 ng/dL
60 years and older 5-32 ng/dL 300-720 ng/dL
Premenopausal (18 years and older) 9-55 ng/dL Does Not Apply
Postmenopausal 5-32 ng/dL Does Not Apply
Tanner Stage I 2-17 ng/dL 2-15 ng/dL
Tanner Stage II 5-40 ng/dL 3-303 ng/dL
Tanner Stage III 10-63 ng/dL 10-851 ng/dL
Tanner Stage IV-V 11-62 ng/dL 162-847 ng/dL

Interpretive Data

Free or bioavailable testosterone measurements may provide supportive information.

For individuals on testosterone-suppressing hormone therapies (e.g., antiandrogens or estrogens), refer to cisgender female reference intervals. For a complete set of all established reference intervals, refer to ltd.aruplab.com/Tests/Pub/0081058.

Compliance Category

Laboratory Developed Test (LDT)


Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
0081058 Testosterone by Mass Spec 2986-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Total Testosterone
Testosterone (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)